Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases

Rationale and design of a double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of nimodipine in preventing cognitive impairment in ischemic cerebrovascular events (NICE)

First author:Penglian Wang

Corresponding author:Tao Feng,Yongjun Wang

essential_information

  • Person in charge:Penglian Wang
  • Data Sources: NICE
  • Number of papers:NICE20150108
  • Published time:2012-09-05

2012-09-05

Published articles

Journal:BMC Neurology

Publication type: Original Contributions

IF(IF): 2.474

PMID: 22950711 Link To Pubmed Full text Download

Background And Purpose

脑血管病已经成为危害我国人民健康的主要疾病之一。目前我国约有700万卒中患者,大约三分之二的卒中患者遗留各种功能障碍。在卒中引起的功能障碍中,不仅有已经受到关注的运动障碍、感觉障碍等,也存在认知障碍甚至卒中后痴呆。卒中后的认知障碍和痴呆可严重影响患者的日常生活能力和生活质量,增加病残率和死亡率。曾经被用于治疗血管性痴呆的药物有胆碱酯酶抑制剂多奈哌齐、重酒石酸卡巴拉汀、NMDA受体拮抗剂美金刚和一些神经营养药物。迄今为止,应用药物治疗血管性痴呆的临床研究尚未得到满意的结果。本研究拟通过多中心、前瞻性、随机分组、双盲、安慰剂对照性研究,评价在急性缺血性卒中后7天内开始尼莫地平口服(30mg, tid)并持续治疗6个月对于急性缺血性卒中后轻度认知障碍防治作用的有效性。

Method

Conclusion

Main results